Mebendazole and Cancer Metabolism: What a New 2026 Glioma Study Suggests

Mebendazole is best known as a prescription medication used to treat certain intestinal worm infections. In recent years, however, researchers have begun investigating whether this established medication might also affect biological pathways involved in cancer growth.

A study published in Cell Reports Medicine in June 2026 has added new evidence to that discussion. Researchers reported that mebendazole, particularly when incorporated into a broader metabolically targeted treatment strategy, reduced tumor progression and invasion in experimental models of pediatric high-grade glioma.

The findings are promising, but they require careful interpretation. This was primarily a laboratory and animal study—not a human clinical trial demonstrating that mebendazole treats cancer. The research does, however, offer important clues about how mebendazole might eventually be studied as part of a combination cancer therapy.

What did the researchers study?

The researchers examined aggressive high-grade gliomas, a category of brain tumors that can be especially difficult to treat in children.

The study used juvenile mice implanted with two different glioma models:

• VM-M3 tumors, which demonstrated extensive invasion through the brain and spinal cord
• CT-2A tumors, which grew within the brain but were less likely to spread to distant areas

The researchers also studied SF-188 cells, a human pediatric high-grade glioma cell line.

Mebendazole and the investigational metabolic medication devimistat were administered as intermittent “pulse” therapies. A high-fat, low-carbohydrate ketogenic diet served as a continuous metabolic intervention intended to place pressure on the tumor’s access to glucose.

The goal was not simply to test whether one medication could kill cancer cells. The researchers wanted to determine whether simultaneously disrupting several sources of tumor energy could produce a stronger response.

What did the study find?

The most favorable results occurred when the medications were administered together with the ketogenic diet.

Compared with control conditions, these combined strategies were associated with:

• Reduced tumor invasion
• Slower tumor progression
• Longer survival in the treated mice
• Lower medication doses in some experimental groups
• Reduced treatment-related toxicity at those lower doses

Mebendazole also reduced the proliferation and viability of the human SF-188 pediatric glioma cells in laboratory testing.

Importantly, the results suggest that the metabolic environment surrounding the tumor may influence how effectively mebendazole works. The study does not indicate that a ketogenic diet or mebendazole is independently sufficient to treat a brain tumor.

How might mebendazole affect cancer cells?

Cancer cells often reorganize their metabolism to support rapid growth, repair and invasion. Glucose is an important source of energy, but many aggressive cancers can also use amino acids such as glutamine when glucose availability is limited.

In the 2026 study, mebendazole inhibited pathways related to both glycolysis—the breakdown of glucose—and glutaminolysis, through which cells use glutamine for energy and cellular building materials.

This may be significant because targeting only one source of tumor energy can allow cancer cells to adapt by increasing their reliance on another source. A treatment capable of interfering with multiple metabolic pathways may make that adaptation more difficult.

Other preclinical research has proposed additional anticancer mechanisms for mebendazole, including disruption of microtubules needed for cell division, interference with tumor blood-vessel formation and promotion of programmed cancer-cell death. These mechanisms remain areas of active investigation rather than established clinical benefits.

A possible benefit as a combination therapy

One of the most important lessons from this study is that mebendazole may be more useful as part of a carefully designed combination than as a stand-alone intervention.

The researchers described their approach as a “press-pulse” strategy. The ketogenic diet provided continuous metabolic pressure, while mebendazole and devimistat were delivered intermittently to target additional tumor vulnerabilities.

This model could offer several theoretical benefits.

First, attacking multiple pathways may reduce the ability of tumor cells to compensate for one blocked energy source.

Second, combining metabolic interventions might allow researchers to use lower doses of certain medications while preserving antitumor activity.

Third, mebendazole is an oral medication with an existing history of human use for parasitic infections. Repurposing an established medication can potentially shorten some aspects of early drug development because basic manufacturing and pharmacology information already exists.

These advantages are theoretical until they are validated in well-controlled human trials.

What do human studies show so far?

Clinical research has established more about the tolerability of mebendazole than its effectiveness against cancer.

A small adult phase 1 trial studied mebendazole in combination with temozolomide, lomustine or radiation-based therapy for recurrent high-grade glioma. Investigators were able to identify doses for further study, although anemia, nausea and fatigue were common. Because phase 1 trials primarily evaluate dosing and safety, the study could not establish that mebendazole improved survival.

A separate phase 1 study published in 2025 enrolled 17 children and young adults with refractory or progressive brain tumors. Mebendazole was tolerated at the studied dose levels, with no dose-limiting toxicities. However, mean progression-free survival was only 7.6 weeks, and the researchers concluded that there was limited evidence of effectiveness when mebendazole was used by itself.

A randomized phase 2 study in recurrent glioblastoma compared mebendazole combined with temozolomide against mebendazole combined with lomustine. Median overall survival was similar between the two groups—approximately 6.7 and 6.4 months. Because both groups received mebendazole, the trial could not determine whether adding mebendazole was better than treatment without it.

Together, these studies show that mebendazole can be investigated clinically, but they do not yet prove that it improves outcomes for people with cancer.

Could lower-dose treatment be an advantage?

The 2026 animal study raises an interesting possibility: changing the tumor’s metabolic environment might allow lower medication doses to produce meaningful effects.

Reducing a medication dose while maintaining therapeutic activity could potentially decrease side effects and improve tolerability. This may be particularly important in pediatric cancer care, where long-term treatment toxicity can affect growth, neurological development and quality of life.

However, a dose that works in a mouse cannot be converted directly into a human treatment protocol. Differences in metabolism, drug absorption, tumor biology and dietary response make direct dose comparisons unreliable.

Patients should never use an experimental animal dose—or a dose promoted online—as a guide for self-treatment.

Mebendazole safety requires medical monitoring

Mebendazole is FDA-approved for specific parasitic infections. It is not FDA-approved as a treatment for cancer.

The doses and treatment durations being investigated in oncology are often substantially greater than those used for routine intestinal infections.

At higher doses or with prolonged use, reported risks include:

• Neutropenia or agranulocytosis
• Abnormal liver tests and hepatitis
• Nausea, vomiting and abdominal symptoms
• Hair loss
• Kidney inflammation
• Serious medication interactions

Mebendazole should not be combined with metronidazole because rare but severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported. Patients receiving prolonged or high-dose therapy may require blood-count and liver-function monitoring.

A ketogenic diet can also produce significant nutritional and metabolic changes. Cancer patients—especially children, people losing weight, and patients receiving chemotherapy—should not begin a restrictive diet without guidance from their oncology team and an appropriately trained dietitian.

What is the most reasonable conclusion?

The new study does not prove that mebendazole cures glioma or any other cancer.

It does strengthen the scientific rationale for studying mebendazole as one component of a metabolically informed combination therapy. In the experimental models, the medication appeared most useful when paired with interventions that simultaneously restricted or disrupted other sources of tumor energy.

The next step is not widespread self-treatment. It is carefully designed clinical research that determines:

• Which cancers are most likely to respond
• Whether metabolic interventions add meaningful benefit
• Which drug combinations are safest
• What doses produce adequate tumor exposure
• Whether treatment improves progression-free or overall survival
• Which biomarkers might identify likely responders

For patients interested in mebendazole, the appropriate starting point is a discussion with a qualified oncologist who understands the patient’s diagnosis, current treatment plan, liver function, blood counts and potential medication interactions.

Personalized prescription support

When a licensed prescriber determines that a compounded medication is clinically appropriate for an individual patient, compounding may provide flexibility in capsule strength, excipient selection and dosage form.

Trinova Health prepares compounded medications only in response to a valid patient-specific prescription. Our pharmacists can work with prescribers to discuss formulation considerations and medication coordination, but decisions about whether mebendazole belongs in a cancer treatment plan must be made by the treating medical team.

Medical disclaimer: This article is provided for educational purposes only and is not medical advice. Mebendazole is not FDA-approved to diagnose, treat, cure or prevent cancer. The research discussed includes laboratory and animal findings that may not translate into clinical benefit for humans. Do not begin, discontinue or modify cancer treatment, mebendazole therapy or a ketogenic diet without consulting a qualified physician. A valid prescription from a licensed practitioner is required for compounded medication.